Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder

Urology Annals

Volumn 3, Issue 2, 2011, Pages 66-70

  Altaweel, Waleed ^a   Mokhtar, Alaa ^a   Rabah, Danny M ^b  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Botox; idiopathic overactive bladder; refractory

Indexed keywords

BOTULINUM TOXIN A; OXYBUTYNIN; TOLTERODINE;

ACUTE DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; HEMATURIA; HUMAN; IDIOPATHIC DISEASE; OUTCOME ASSESSMENT; OUTPATIENT CARE; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TERTIARY HEALTH CARE; TOTAL QUALITY MANAGEMENT; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION; URODYNAMICS;

EID: 79959996667     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.82170     Document Type: Article

References (18)

1. Abrams P, Blaivas JG, Fowler CJ, Fourcroy JL, Macdiarmid SA, Siegel SW, et al. The role of neuromodulation in themanagement of urinary urge incontinence. BJU Int 2003;91:355-9. (Pubitemid 36359641)
2. Herschorn S, Hewitt RJ. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 1998;52:672-8. (Pubitemid 28440179)
3. Van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. Zeitsch Hyg Infekt 1897;26:1-56.
4. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995;28:423-72. (Pubitemid 26015975)
5. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-82. (Pubitemid 41140654)
6. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002;6:460-9.
7. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325-6. (Pubitemid 36966603)
8. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868-72.
9. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 2004;63:1071-5. (Pubitemid 38746805)
10. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231-6. (Pubitemid 40617096)
11. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-9. (Pubitemid 41140656)
12. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22.
13. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78. (Pubitemid 34195211)
14. Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stöhrer M. Standarization of outcome studies in patients with lower urinary tract dysfunction: A report on general principles from standardization committee of international continence society. Neurourol Urodyn 1998;17:249-53. (Pubitemid 28201709)
15. Cohen BL, Barboglio P, Rodriguez D, Gousse AE. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009;28:205-8.
16. Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: Results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-15.
17. Khan S, Kessler TM, Apostolidis A, Kalsi V, Panicker J, Roosen A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009;181:1773-8.
18. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-85. (Pubitemid 43815416)